Literature DB >> 26614372

Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors.

Nitya Raj1, Diane Reidy-Lagunes2.   

Abstract

Pancreatic neuroendocrine tumors are an uncommon tumor type and compose 1% to 2% of all pancreatic neoplasms. They are rarely localized at presentation and are typically diagnosed in the presence of metastatic disease. The management poses a significant challenge because of the heterogeneous clinical presentations and varying degrees of aggressiveness. A variety of systemic therapies have been developed for the management of pancreatic neuroendocrine tumors, including somatostatin analogues, a select group of cytotoxic chemotherapy agents, and targeted or biological agents. This article reviews the available systemic therapy options for advanced pancreatic neuroendocrine tumors.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Carcinoid tumors; Everolimus; Lanreotide; Neuroendocrine tumors; Octreotide; Pancreatic neuroendocrine tumors; Sunitinib

Mesh：

Substances：

Year:  2015        PMID： 26614372      PMCID： PMC5046222          DOI： 10.1016/j.hoc.2015.09.005

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  55 in total

1.  The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.

Authors:  Olca Basturk; Zhaohai Yang; Laura H Tang; Ralph H Hruban; Volkan Adsay; Chad M McCall; Alyssa M Krasinskas; Kee-Taek Jang; Wendy L Frankel; Serdar Balci; Carlie Sigel; David S Klimstra
Journal:  Am J Surg Pathol       Date:  2015-05       Impact factor: 6.394

2.  NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors.

Authors:  Orlo H Clark; Al B Benson; Jordan D Berlin; Michael A Choti; Gerard M Doherty; Paul F Engstrom; John F Gibbs; Martin J Heslin; Anne Kessinger; Matthew H Kulke; Larry Kvols; Riad Salem; Leonard Saltz; Manisha H Shah; Stephen Shibata; Jonathan R Strosberg; James C Yao
Journal:  J Natl Compr Canc Netw       Date:  2009-07       Impact factor: 11.908

3.  Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin.

Authors:  I M Murray-Lyon; A L Eddleston; R Williams; M Brown; B M Hogbin; A Bennett; J C Edwards; K W Taylor
Journal:  Lancet       Date:  1968-10-26       Impact factor: 79.321

4.  Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors.

Authors:  Jonathan R Strosberg; Asima Cheema; Jill Weber; Gang Han; Domenico Coppola; Larry K Kvols
Journal:  J Clin Oncol       Date:  2011-06-27       Impact factor: 44.544

5.  Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

Authors:  Christian Waldherr; Miklos Pless; Helmut R Maecke; Tilmann Schumacher; Armin Crazzolara; Egbert U Nitzsche; Andreas Haldemann; Jan Mueller-Brand
Journal:  J Nucl Med       Date:  2002-05       Impact factor: 10.057

6.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Authors:  Eric Raymond; Laetitia Dahan; Jean-Luc Raoul; Yung-Jue Bang; Ivan Borbath; Catherine Lombard-Bohas; Juan Valle; Peter Metrakos; Denis Smith; Aaron Vinik; Jen-Shi Chen; Dieter Hörsch; Pascal Hammel; Bertram Wiedenmann; Eric Van Cutsem; Shem Patyna; Dongrui Ray Lu; Carolyn Blanckmeister; Richard Chao; Philippe Ruszniewski
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

Review 7.  Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors.

Authors:  Daniel Castellano; Enrique Grande; Juan Valle; Jaume Capdevila; Diane Reidy-Lagunes; Juan Manuel O'Connor; Eric Raymond
Journal:  Cancer Chemother Pharmacol       Date:  2014-12-06       Impact factor: 3.333

Review 8.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

9.  Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours.

Authors:  N C Turner; S J Strauss; D Sarker; R Gillmore; A Kirkwood; A Hackshaw; A Papadopoulou; J Bell; I Kayani; C Toumpanakis; F Grillo; A Mayer; D Hochhauser; R H Begent; M E Caplin; T Meyer
Journal:  Br J Cancer       Date:  2010-03-16       Impact factor: 7.640

10.  Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.

Authors:  James C Yao; Alexandria T Phan; David Z Chang; Robert A Wolff; Kenneth Hess; Sanjay Gupta; Carmen Jacobs; Jeannette E Mares; Andrea N Landgraf; Asif Rashid; Funda Meric-Bernstam
Journal:  J Clin Oncol       Date:  2008-09-10       Impact factor: 44.544
View more
  7 in total

Review 1.  Update in the Therapy of Advanced Neuroendocrine Tumors.

Authors:  Inbal Uri; Shani Avniel-Polak; David J Gross; Simona Grozinsky-Glasberg
Journal:  Curr Treat Options Oncol       Date:  2017-11-16

2.  Reassessing the grade of gastroenteropancreatic neuroendocrine neoplasms.

Authors:  David S Klimstra
Journal:  Endocrine       Date:  2016-05-05       Impact factor: 3.633

Review 3.  Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights.

Authors:  Jason S Starr; Mohamad Bassam Sonbol; Timothy J Hobday; Akash Sharma; Ayse Tuba Kendi; Thorvardur R Halfdanarson
Journal:  Onco Targets Ther       Date:  2020-04-28       Impact factor: 4.147

4.  Prognosis analysis of patients with pancreatic neuroendocrine tumors after surgical resection and the application of enucleation.

Authors:  Junzhang Chen; Yongyu Yang; Yuanhua Liu; Heping Kan
Journal:  World J Surg Oncol       Date:  2021-01-12       Impact factor: 2.754

5.  Platinum-Based Treatment for Well- and Poorly Differentiated Pancreatic Neuroendocrine Neoplasms.

Authors:  Alessandra Pulvirenti; Nitya Raj; Sara Cingarlini; Antonio Pea; Laura H Tang; Claudio Luchini; Joanne F Chou; Elisabetta Grego; Ioana Marinova; Marinela Capanu; Luca Landoni; Aldo Scarpa; Peter J Allen; David S Klimstra; Diane L Reidy-Lagunes
Journal:  Pancreas       Date:  2021-02-01       Impact factor: 3.243

Review 6.  Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Authors:  Inbal Uri; Simona Grozinsky-Glasberg
Journal:  Clin Diabetes Endocrinol       Date:  2018-07-11

7.  Tumor Contrast-Enhancement for Monitoring of PRRT 177Lu-DOTATATE in Pancreatic Neuroendocrine Tumor Patients.

Authors:  Olof Pettersson; Katarzyna Fröss-Baron; Joakim Crona; Anders Sundin
Journal:  Front Oncol       Date:  2020-02-21       Impact factor: 6.244
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.